VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

Feline immunodeficiency virus recombinant vector vaccine FIVΔRT
Vaccine Information
  • Vaccine Name: Feline immunodeficiency virus recombinant vector vaccine FIVΔRT
  • Target Pathogen: Feline immunodeficiency virus
  • Target Disease: Feline AIDS
  • Vaccine Ontology ID: VO_0004550
  • Type: Recombinant vector vaccine
  • Status: Research
  • Immunization Route: Intramuscular injection (i.m.)
Host Response

Cat Response

  • Vaccination Protocol: Kittens, which were 12 weeks old, were randomized into groups of five for immunization. DNA was administered at four sites in the gastrocnemius and quadriceps muscles (100 μg of each DNA in a total of 200 μl of PBS at each site) (Hosie et al., 1998).
  • Vaccine Immune Response Type: VO_0003057
  • Immune Response: The bias toward CTL induction rather than antibody production in response to inoculation with FIVΔRT suggested that intramuscular administration of the FIVΔRT DNA generated primarily a Th1-type immune response (Hosie et al., 1998).
  • Challenge Protocol: The cats were challenged with the homologous F-14 molecular clone of the FIV-PET isolate that had been subjected to titer determination by intraperitoneal inoculation of age-matched cats to calculate the 50% infectious dose (Hosie et al., 1998).
  • Efficacy: At 6, 9, and 12 weeks postchallenge, one of five FIVΔRT vaccinates and three of five FIVΔRT-plus-IFN-γ vaccinates remained virus free. In contrast, virus was isolated consistently from all of the control cats (IFN-γ alone and no-DNA control groups) at 6, 9, and 12 weeks postchallenge (Hosie et al., 1998).
References